open access
HSPA5 is a prognostic biomarker correlated with immune infiltrates in thyroid carcinoma
, , 1
Affiliations- Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
open access
Abstract
Introduction: Thyroid carcinoma (THCA) is the most common endocrine malignancy. Recent research has shown heat shock protein family A (HSPA5) as a diagnostic and prognostic biomarker for various malignancies. Nevertheless, the role of HSPA5 in THCA is unclear.
This study aims to explore HSPA5 expression in THCA and its potential diagnostic and therapeutic value for THCA.
Material and methods: We obtained the data of HSPA5 expression in THCA and normal thyroid tissues from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). We used the Shapiro-Wilk normality test, Levene’s test, t-test, Dunn’s test, Kruskal-Wallis test, Wilcoxon rank sum test, chi-square test, Fisher’s exact test, and logistic regression to evaluate the relationship between the expression of HSPA5 and clinicopathological features. Kaplan-Meier method and Cox regression were applied to analyse the correlation between the expression level of HSPA5 and prognosis of THCA patients, and to construct a prognosis prediction model of THCA patients. Gene set enrichment analysis (GSEA) was applied to explore the potential pathway related to HSPA5 in THCA.
Results: HSPA5 expression was lower in THCA tissues than in normal thyroid tissues (p < 0.001). Low expression of HSPA5 in THCA patients was related to poorer T stage (p < 0.001), N stage (p < 0.001), pathologic stage (p < 0.001), tumour extrathyroidal extension (p < 0.001), residual tumour (p = 0.03), and progression-free interval (PFI) event (p = 0.002). Low HSPA5 expression was associated with poor PFI.
According to the results of univariate analysis, THCA patients who had high HSPA5 levels had longer PFI (p = 0.042). Enrichment analysis via GO/KEGG showed that the top 10 genes related to HSPA5 were all enriched in the pathways related to endoplasmic reticulum function. Moreover, HSPA5 expression was related to immune infiltrating cells.
Conclusions: Decreased expression of HSPA5 is associated with worse clinicopathological features, shorter PFI and higher immune infiltration level of multiple immune cells, which demonstrated that HSPA5 is a prognostic biomarker in THCA.
Abstract
Introduction: Thyroid carcinoma (THCA) is the most common endocrine malignancy. Recent research has shown heat shock protein family A (HSPA5) as a diagnostic and prognostic biomarker for various malignancies. Nevertheless, the role of HSPA5 in THCA is unclear.
This study aims to explore HSPA5 expression in THCA and its potential diagnostic and therapeutic value for THCA.
Material and methods: We obtained the data of HSPA5 expression in THCA and normal thyroid tissues from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). We used the Shapiro-Wilk normality test, Levene’s test, t-test, Dunn’s test, Kruskal-Wallis test, Wilcoxon rank sum test, chi-square test, Fisher’s exact test, and logistic regression to evaluate the relationship between the expression of HSPA5 and clinicopathological features. Kaplan-Meier method and Cox regression were applied to analyse the correlation between the expression level of HSPA5 and prognosis of THCA patients, and to construct a prognosis prediction model of THCA patients. Gene set enrichment analysis (GSEA) was applied to explore the potential pathway related to HSPA5 in THCA.
Results: HSPA5 expression was lower in THCA tissues than in normal thyroid tissues (p < 0.001). Low expression of HSPA5 in THCA patients was related to poorer T stage (p < 0.001), N stage (p < 0.001), pathologic stage (p < 0.001), tumour extrathyroidal extension (p < 0.001), residual tumour (p = 0.03), and progression-free interval (PFI) event (p = 0.002). Low HSPA5 expression was associated with poor PFI.
According to the results of univariate analysis, THCA patients who had high HSPA5 levels had longer PFI (p = 0.042). Enrichment analysis via GO/KEGG showed that the top 10 genes related to HSPA5 were all enriched in the pathways related to endoplasmic reticulum function. Moreover, HSPA5 expression was related to immune infiltrating cells.
Conclusions: Decreased expression of HSPA5 is associated with worse clinicopathological features, shorter PFI and higher immune infiltration level of multiple immune cells, which demonstrated that HSPA5 is a prognostic biomarker in THCA.
Keywords
thyroid carcinoma; HSPA5; endoplasmic reticulum protein; prognosis; immune cell infiltration; bioinformatics analysis
About this articleTitle
HSPA5 is a prognostic biomarker correlated with immune infiltrates in thyroid carcinoma
Journal
Issue
Article type
Original paper
Pages
680-689
Published online
2022-06-29
Page views
4413
Article views/downloads
614
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2022;73(4):680-689.
Keywords
thyroid carcinoma
HSPA5
endoplasmic reticulum protein
prognosis
immune cell infiltration
bioinformatics analysis
Authors
Wenge Dong
Danwei Du
Hai Huang
References (35)- Siegel RL, Miller KD, Goding Sauer A, et al. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30.
- Dong W, Horiuchi K, Tokumitsu H, et al. Time-Varying Pattern of Mortality and Recurrence from Papillary Thyroid Cancer: Lessons from a Long-Term Follow-Up. Thyroid. 2019; 29(6): 802–808.
- Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016; 1: 15004.
- Pstrąg N, Ziemnicka K, Bluyssen H, et al. Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates. Mol Cancer. 2018; 17(1): 116.
- Wang J, Lee J, Liem D, et al. HSPA5 Gene encoding Hsp70 chaperone BiP in the endoplasmic reticulum. Gene. 2017; 618: 14–23.
- Kim SY, Kim HJ, Kim HJ, et al. HSPA5 negatively regulates lysosomal activity through ubiquitination of MUL1 in head and neck cancer. Autophagy. 2018; 14(3): 385–403.
- Yip CW, Lam CY, Poon TCW, et al. Granulin-epithelin precursor interacts with 78-kDa glucose-regulated protein in hepatocellular carcinoma. BMC Cancer. 2017; 17(1): 409.
- Xia S, Duan W, Liu W, et al. GRP78 in lung cancer. J Transl Med. 2021; 19(1): 118.
- Miura Y, Kaira K, Sakurai R, et al. High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. Int J Clin Oncol. 2017; 22(5): 872–879.
- Langer R, Feith M, Siewert JR, et al. Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer. 2008; 8: 70.
- Liu J, Lichtenberg T, Hoadley K, et al. An integrated TCGA pan-cancer clinical data resource to drive high quality survival outcome analytics. Cell. 2018; 173(2): 400–416.
- Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14: 7.
- Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4): 782–795.
- Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2008; 7(12): 1013–1030.
- Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol. 2004; 14(1): 20–28.
- Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods. 2005; 35(4): 373–381.
- Ibrahim IM, Abdelmalek DH, Elfiky AA. GRP78: A cell's response to stress. Life Sci. 2019; 226: 156–163.
- Zhang LH, Zhang X. Roles of GRP78 in physiology and cancer. J Cell Biochem. 2010; 110(6): 1299–1305.
- Farshbaf M, Khosroushahi AY, Mojarad-Jabali S, et al. Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer. J Control Release. 2020; 328: 932–941.
- Qiu X, Guan X, Liu W, et al. DAL-1 attenuates epithelial to mesenchymal transition and metastasis by suppressing HSPA5 expression in non-small cell lung cancer. Oncol Rep. 2017; 38(5): 3103–3113.
- Chen HA, Chang YW, Tseng CF, et al. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer. Ann Surg Oncol. 2015; 22(3): 889–898.
- Dong D, Stapleton C, Luo B, et al. A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res. 2011; 71(8): 2848–2857.
- Yang Z, Zhuang L, Szatmary P, et al. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. Int J Med Sci. 2015; 12(3): 256–263.
- Zhao G, Kang J, Jiao K, et al. High Expression of GRP78 Promotes Invasion and Metastases in Patients with Esophageal Squamous Cell Carcinoma. Dig Dis Sci. 2015; 60(9): 2690–2699.
- Teng Y, Ai Z, Wang Y, et al. Proteomic identification of PKM2 and HSPA5 as potential biomarkers for predicting high-risk endometrial carcinoma. J Obstet Gynaecol Res. 2013; 39(1): 317–325.
- Ogawa H, Kaira K, Takahashi K, et al. Prognostic role of BiP/GRP78 expression as ER stress in patients with gastric adenocarcinoma. Cancer Biomark. 2017; 20(3): 273–281.
- Yang C, Zhang Z, Zou Y, et al. Expression of glucose-regulated protein 78 as prognostic biomarkers for triple-negative breast cancer. Histol Histopathol. 2020; 35(6): 559–568.
- Wei PL, Kuo LJ, Wang W, et al. Silencing of glucose-regulated protein 78 (GRP78) enhances cell migration through the upregulation of vimentin in hepatocellular carcinoma cells. Ann Surg Oncol. 2012; 19 Suppl 3: S572–S579.
- Davidson DJ, Haskell C, Majest S, et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res. 2005; 65(11): 4663–4672.
- Burikhanov R, Zhao Y, Goswami A, et al. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell. 2009; 138(2): 377–388.
- Verfaillie T, Garg AD, Agostinis P. Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett. 2013; 332(2): 249–264.
- Farhood B, Najafi M, Mortezaee K. CD8 cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019; 234(6): 8509–8521.
- Li TJ, Wang WQ, Yu XJ, et al. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2020; 1874(1): 188384.
- Basu A, Ramamoorthi G, Albert G, et al. Differentiation and Regulation of T Cells: A Balancing Act for Cancer Immunotherapy. Front Immunol. 2021; 12: 669474.
- Xie J, Fu L, Jin Li. Immunotherapy of gastric cancer: Past, future perspective and challenges. Pathol Res Pract. 2021; 218: 153322.
